|Bid||739.75 x 900|
|Ask||745.49 x 1000|
|Day's range||745.05 - 755.87|
|52-week range||538.01 - 769.63|
|Beta (5Y monthly)||0.21|
|PE ratio (TTM)||15.14|
|Earnings date||02 Feb 2023 - 06 Feb 2023|
|Forward dividend & yield||N/A (N/A)|
|1y target est||802.25|
The list includes Regeneron Pharmaceuticals (NASDAQ: REGN) and Biogen (NASDAQ: BIIB). Regeneron was having an unimpressive year on the stock market until its shares soared by double-digit percentages in one day in September. As is often the case with biotechs, Regeneron owes this move to positive clinical developments.
The FDA accepts for priority review Regeneron's (REGN) sBLA for Evkeeza for treating children aged five to 11 years with homozygous familial hypercholesterolemia. A decision is due on Mar 30, 2023.
A couple of stocks that have been hot buys this year are Regeneron Pharmaceuticals (NASDAQ: REGN) and T-Mobile US (NASDAQ: TMUS). Unlike the S&P 500, which is down about 17% this year, these two stocks have generated positive returns of 15% or more. Here's a closer look at why both of these stocks can still soar higher in 2023.